At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow.

Despite failing to achieve one of the co-primary endpoints of the SENTRY study, Karyopharm will still approach the FDA for ...

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported topline results from its Phase 3 SENTRY trial, a randomized, ...

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM ...

Eating more meat in mid-life could help protect against dementia if you have the gene that has been linked to more than 90 ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares rose 10% on Tuesday after the company reported mixed results from its Phase ...

A growing body of evidence suggests that a single gene, APOE, may play a far more dominant role in Alzheimer’s disease than ...

Rare medical events draw intense attention during any mass vaccination campaign. Among COVID vaccine side effects, few ...

While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS - - SENTRY ...

Shares of Karyopharm Therapeutics KPTI plunged 18.3% on Tuesday after the company reported mixed top-line results from a late ...

D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is ...

Some people with the gene did not have expected outcomes if they were heavy meat-eaters ...